ArticleJTCVS open2026
Transitioning from neoadjuvant chemoradiation to perioperative chemotherapy for esophageal adenocarcinoma: Impact on margins and pathologic outcomes.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Treatment of esophageal adenocarcinoma has historically involved trimodality therapy. Recently, perioperative chemotherapy has become standard of care due to improved survival. We investigated the implications of this change on surgical and pathologic outcomes. Methods: This multicenter retrospective analysis included adults who underwent esophagogastrectomy for esophageal/gastroesophageal junction adenocarcinoma between 2023 and 2025. The primary outcome was any positive margin on final pathology. Secondary outcomes included rates of nodal upstage and posttreatment tumor characteristics. Fisher exact and Kruskal-Wallis tests were used for comparisons. Results: In total, 110 patients were included; 22 received perioperative chemotherapy (20.0%), 48 chemoradiation (chemoRT, 43.6%), and 40 induction chemotherapy followed by chemoRT (chemo + chemoRT, 36.3%). On final pathology, 36.4% of patients experienced nodal upstaging in the chemotherapy group (n = 8) relative to 16.7% (n = 8) and 7.5% (n = 3) in the chemoRT and chemo + chemoRT groups ( Conclusions: In this small multi-institutional study, chemotherapy-only preoperative regimens seemed to be associated with increased rates of nodal upstage and margin positivity after esophagectomy relative to radiotherapy-inclusive protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.